HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bennink, R. J. Articles by Sloof, G. W. Search for Related Content PubMed PubMed Citation Articles by Bennink, R. J. Articles by Sloof, G. W.

Estrogen Receptor Status in Primary Breast Cancer: Iodine 123–labeled cis-11ß-Methoxy-17-iodovinyl Estradiol Scintigraphy¹

¹ From the Departments of Nuclear Medicine (R.J.B., L.J.R., G.W.S.), Radiotherapy (G.v.T.), and Pathology (L.A.N.), Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; and Nycomed Amersham Cygne and Eindhoven University of Technology, Eindhoven, the Netherlands (L.J.R., A.G.J.). From the 2000 RSNA scientific assembly. Received October 10, 2000; revision requested November 25; final revision received March 30, 2001; accepted April 4. Address correspondence to R.J.B. (e-mail: r.bennink@amc.uva.nl).

PURPOSE: To determine the sensitivity of iodine 123 (¹²³I)–labeled cis-11ß-methoxy-17-iodovinyl estradiol (Z-MIVE) scintigraphy for the detection of estrogen receptors in patients with primary breast carcinoma.

MATERIALS AND METHODS: In 22 patients, estrogen receptor status was assessed with planar scintigraphy and single photon emission computed tomography (SPECT) 4 hours after the injection of 185 MBq ¹²³I-labeled Z-MIVE. For histologic and estrogen receptor immunohistochemical analysis, breast carcinoma tissue was obtained in all patients by means of biopsy or resection of the primary tumor. Two experienced physicians semiquantitatively scored the scintigraphic and immunohistochemical findings. The uptake ratio at scintigraphy and the immunohistologic staining intensity were scored as negative, weak, intermediate, or strong.

RESULTS: All patients had histologically proven breast cancer. Immunohistologic staining for estrogen receptors yielded negative findings in four patients and positive findings in 18 (weak staining, n = 2; intermediate staining, n = 6; strong staining, n = 10). Planar ¹²³I-labeled Z-MIVE scintigraphic findings were negative in five patients and positive in 17 (weak uptake, n = 2; intermediate uptake, n = 10; strong uptake, n = 5), resulting in one false-negative finding. Findings at ¹²³I-labeled Z-MIVE SPECT were negative in four patients and positive in 18. The sensitivities of ¹²³I-labeled Z-MIVE scintigraphy for estrogen receptors were 100% with SPECT and 94% with planar scintigraphy. The correlation between immunohistologic and planar scintigraphic scores of estrogen receptor status was 0.72 (P < .01).

CONCLUSION: ¹²³I-labeled Z-MIVE scintigraphy is a sensitive noninvasive tool for the detection of estrogen receptors in patients with breast cancer.

Index terms: Breast neoplasms, radionuclide studies, 00.12161, 00.32 • Breast neoplasms, SPECT, 00.12162, 00.32 • Hormones

This article has been cited by other articles:

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]

				B. Van Den Bossche and C. Van de Wiele Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607. [Abstract] [Full Text] [PDF]

				R. J. Bennink, G. van Tienhoven, L. J. Rijks, A. L. Noorduyn, A. G. Janssen, and G. W. Sloof In Vivo Prediction of Response to Antiestrogen Treatment in Estrogen Receptor-Positive Breast Cancer J. Nucl. Med., January 1, 2004; 45(1): 1 - 7. [Abstract] [Full Text] [PDF]